Company: MIRM
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001759425-25-000054
Chunk: 353

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 353
---
 Months Ended September 30,Nine Months Ended September 30, 2025202420252024United States$103,713 $73,905 $286,167 $195,096 Rest of the world29,297 16,397 86,213 41,883 Total product sales, net$133,010 $90,302 $372,380 $236,979 Foreign CurrencyThe unaudited condensed consolidated financial statements are presented in U.S. dollars. The functional currency for most of the Company’s foreign subsidiaries is their local currency. Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period. Income statement items are 

9

translated at average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity.Foreign currency transaction gains and losses are included in other income (expense), net in the unaudited condensed consolidated statements of operations. Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction. Unrealized foreign exchange gains amounted to $0.6 million for the three months ended September 30, 2025 and unrealized foreign exchange losses amounted to $1.0 million for the three months ended September 30, 2024. Unrealized foreign exchange gains amounted to $1.9 million and $1.1 million for the nine months ended September 30, 2025 and 2024, respectively. Realized foreign exchange losses amounted to $0.2 million and $1.0 million for the three and nine months ended September 30, 2025, and were not material for the three and nine months ended September 30, 2024.Net Income (Loss) Per ShareBasic net income (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net income (loss) per share is computed by dividing the net income (loss) by the weighted-average shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. Diluted net income (loss) per share excludes the potential impact of the Company’s common stock subject to repurchase, common stock options, restricted stock units, contingently issuable employee stock purchase plan shares and common